|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4409450A
(en)
|
1982-07-29 |
1983-10-11 |
Amp Incorporated |
Double pole membrane switch having preferred sequence closing feature
|
|
IL71275A0
(en)
|
1983-03-21 |
1984-06-29 |
Sparamedica Ag |
Human interleukin-2-and its preparation
|
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
AU7906691A
(en)
|
1990-05-23 |
1991-12-10 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Adeno-associated virus (aav)-based eucaryotic vectors
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
WO1993021173A1
(en)
|
1992-04-17 |
1993-10-28 |
Abbott Laboratories |
Taxol derivatives
|
|
EP0673431A1
(en)
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
KR100310510B1
(ko)
|
1993-03-23 |
2002-07-04 |
장 스테판느 |
3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
CA2144040A1
(fr)
|
1993-07-13 |
1995-01-26 |
Michel Perricaudet |
Vecteurs adenoviraux defectifs et utilisation en therapie genique
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
AU713040B2
(en)
|
1994-07-15 |
1999-11-18 |
University Of Iowa Research Foundation, The |
Immunomodulatory oligonucleotides
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US5912264A
(en)
|
1997-03-03 |
1999-06-15 |
Bristol-Myers Squibb Company |
6-halo-or nitrate-substituted paclitaxels
|
|
CA2309688C
(en)
|
1997-11-10 |
2007-04-24 |
Cellegy Pharmaceuticals, Inc. |
Penetration enhancing and irritation reducing systems
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AT406376B
(de)
|
1998-01-16 |
2000-04-25 |
Immuno Ag |
Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
|
|
JPH11268865A
(ja)
|
1998-03-20 |
1999-10-05 |
Omron Corp |
用紙仕分け装置及び方法
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
US6198323B1
(en)
|
1999-01-28 |
2001-03-06 |
Lucent Technologies Inc. |
Flip-flop having gated inverter feedback structure with embedded preset/clear logic
|
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US20030180352A1
(en)
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6967023B1
(en)
|
2000-01-10 |
2005-11-22 |
Foamix, Ltd. |
Pharmaceutical and cosmetic carrier or composition for topical application
|
|
CO5280224A1
(es)
|
2000-02-02 |
2003-05-30 |
Univ Florida State Res Found |
Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
|
|
KR100880765B1
(ko)
|
2000-03-14 |
2009-02-02 |
버베리안 노딕 에이/에스 |
변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
|
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Ｒｎａ干渉の方法とｒｎａ干渉組成物
|
|
DE60116075T4
(de)
|
2000-04-25 |
2007-06-06 |
Immunex Corp., Thousand Oaks |
Behandlung von tumoren mit photodynamischer therapie
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
WO2001091802A1
(en)
|
2000-05-30 |
2001-12-06 |
Baylor College Of Medicine |
Chimeric viral vectors for gene therapy
|
|
US8512718B2
(en)
|
2000-07-03 |
2013-08-20 |
Foamix Ltd. |
Pharmaceutical composition for topical application
|
|
US7030099B2
(en)
|
2000-07-21 |
2006-04-18 |
Research Corporation Technologies, Inc. |
Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells
|
|
AU2002211490A1
(en)
|
2000-10-04 |
2002-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of using capsid protein from flaviviruses and pestiviruses
|
|
EP1213025A1
(de)
|
2000-12-06 |
2002-06-12 |
Laboratoires Serobiologiques(Societe Anonyme) |
Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa
|
|
EP1341817A2
(en)
|
2000-12-08 |
2003-09-10 |
Novo Nordisk A/S |
Tff peptides
|
|
WO2002092134A1
(en)
|
2001-05-14 |
2002-11-21 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
JP2003009883A
(ja)
|
2001-07-05 |
2003-01-14 |
Mitsubishi Pharma Corp |
マスト細胞の細胞死誘発剤
|
|
AU2002350409A1
(en)
|
2001-10-26 |
2003-05-06 |
Uffe Holmskov |
Surfactant protein-d and atherosclerosis
|
|
US7368122B1
(en)
|
2002-03-08 |
2008-05-06 |
Dow Pharmaceutical Sciences |
Skin cream
|
|
WO2004014314A2
(en)
|
2002-08-12 |
2004-02-19 |
David Kirn |
Methods and compositions concerning poxviruses and cancer
|
|
ATE350383T1
(de)
|
2002-08-23 |
2007-01-15 |
Sloan Kettering Inst Cancer |
Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
|
|
GB0226251D0
(en)
|
2002-11-11 |
2002-12-18 |
San Raffaele Centro Fond |
Acetylated protein
|
|
US20040143026A1
(en)
|
2002-12-31 |
2004-07-22 |
Shah Kishore R. |
Bioadhesive hydrophilic composition for treatment of mammalian skin
|
|
NZ570709A
(en)
|
2003-06-13 |
2010-04-30 |
Univ Pennsylvania |
Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
|
|
MXPA05013879A
(es)
|
2003-06-18 |
2006-06-27 |
Genelux Corp |
Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
|
|
AU2004272607B2
(en)
|
2003-09-11 |
2008-11-06 |
Cornerstone Therapeutics Inc. |
Monoclonal antibodies against HMGB1
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
JP4719855B2
(ja)
|
2003-12-05 |
2011-07-06 |
国立大学法人北海道大学 |
高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
|
|
DE102004030044A1
(de)
|
2004-06-22 |
2006-01-12 |
Birken Gmbh |
Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
|
|
ES2433467T3
(es)
|
2005-01-20 |
2013-12-11 |
Isconova Ab |
Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
|
|
US20100094560A1
(en)
|
2006-08-15 |
2010-04-15 |
Prometheus Laboratories Inc. |
Methods for diagnosing irritable bowel syndrome
|
|
DK2402451T3
(en)
|
2006-08-25 |
2018-06-25 |
The Government Of The Us Secretary Department Of Health And Human Services |
Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
|
|
WO2008023077A2
(en)
|
2006-08-25 |
2008-02-28 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Compositions and methods for modulating an immune response
|
|
EP2415783B1
(en)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
GB0702695D0
(en)
|
2007-02-12 |
2007-03-21 |
Ark Therapeutics Ltd |
Production of vectors
|
|
US8003363B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
EP2484691B1
(en)
|
2007-07-10 |
2016-01-13 |
Apogenix GmbH |
TNF superfamily collectin fusion proteins
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
CN101970650B
(zh)
|
2008-03-06 |
2017-07-25 |
哈洛齐梅公司 |
可溶性透明质酸酶的大规模生产
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
PT2119726E
(pt)
|
2008-05-14 |
2015-03-30 |
Immatics Biotechnologies Gmbh |
Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
|
|
US10603351B2
(en)
|
2008-08-21 |
2020-03-31 |
Turnstone Limited Partnership |
Engineered synergistic oncolytic viral symbiosis
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
EP2184297A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G polypeptides and pharmaceutical uses thereof
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
CA2709292A1
(en)
|
2009-07-10 |
2011-01-10 |
The Governors Of The University Of Alberta |
Oncolytic viruses and methods for treating neoplastic disorders
|
|
EP2617426B1
(en)
|
2010-09-17 |
2016-08-10 |
Japan Science and Technology Agency |
Inhibitor of hmgb protein-mediated immune response activation
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
US9919047B2
(en)
|
2011-01-04 |
2018-03-20 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
EP2527459A1
(en)
|
2011-05-02 |
2012-11-28 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Blood-based gene detection of non-small cell lung cancer
|
|
KR102022952B1
(ko)
|
2011-08-05 |
2019-09-20 |
신라젠(주) |
백시니아 바이러스의 생산을 위한 방법 및 조성물
|
|
FI20115914L
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10806697B2
(en)
|
2012-12-21 |
2020-10-20 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
|
US9862932B2
(en)
|
2012-07-24 |
2018-01-09 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
IN2015DN02335A
(enExample)
|
2012-09-28 |
2015-08-28 |
Probiogen Ag |
|
|
US9180091B2
(en)
|
2012-12-21 |
2015-11-10 |
Therapeuticsmd, Inc. |
Soluble estradiol capsule for vaginal insertion
|
|
KR20140122603A
(ko)
|
2013-04-10 |
2014-10-20 |
신라젠(주) |
세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포
|
|
EP3461491B1
(en)
|
2013-04-18 |
2024-11-13 |
TILT Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
KR102322510B1
(ko)
|
2013-07-18 |
2021-11-08 |
브이아이비 브이지더블유 |
수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
|
|
ES2847305T3
(es)
|
2013-08-22 |
2021-08-02 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Terapias inmunooncolíticas
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
EA201691765A1
(ru)
*
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
MA39818A
(fr)
|
2014-03-30 |
2017-02-08 |
Benevir Biopharm Inc |
Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
|
|
US20160060313A1
(en)
|
2014-08-27 |
2016-03-03 |
Daewoong Jo |
Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same
|
|
EP3186281B1
(en)
*
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
AU2015332533B2
(en)
*
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
EP3203281B1
(en)
|
2014-10-24 |
2020-12-09 |
Huawei Technologies Co., Ltd. |
Mode multiplexer-demultiplexer and switching node
|
|
EP4122492A1
(en)
|
2015-02-25 |
2023-01-25 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
EP3217993A1
(en)
|
2015-07-20 |
2017-09-20 |
Virttu Biologics Limited |
Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
|
|
HK1255192A1
(zh)
|
2015-09-08 |
2019-08-09 |
Sillajen, Inc. |
表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
CN109152815B
(zh)
|
2016-02-25 |
2022-10-18 |
纪念斯隆凯特琳癌症中心 |
用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
JP2019528753A
(ja)
*
|
2016-09-21 |
2019-10-17 |
スティーブン エイチ． ソーン， |
高移動度グループｂｏｘｉ突然変異体
|
|
US20200046784A1
(en)
|
2016-09-30 |
2020-02-13 |
University Health Network |
Recombinant oncolytic viruses for cancer therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
US11185586B2
(en)
|
2016-11-22 |
2021-11-30 |
Alloplex Biotherapeutics, Inc. |
Allogeneic tumor cell vaccine
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
AU2018223211B2
(en)
|
2017-02-21 |
2025-02-27 |
Adelaide university |
T cells expressing chemokine receptors for treating cancer
|
|
TWI672677B
(zh)
|
2017-03-31 |
2019-09-21 |
鈺立微電子股份有限公司 |
用以融合多深度圖的深度圖產生裝置
|
|
US20200268831A1
(en)
|
2017-09-15 |
2020-08-27 |
The Texas A&M University System |
Methods for enhancing immunotherapy in the treatment of cancer
|
|
WO2019089755A1
(en)
|
2017-10-31 |
2019-05-09 |
Western Oncolytics Ltd. |
Platform oncolytic vector for systemic delivery
|
|
JP2021511060A
(ja)
|
2018-01-26 |
2021-05-06 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
|
|
CA3099330A1
(en)
|
2018-05-02 |
2019-11-07 |
Tonix Pharma Holdings Limited |
Synthetic chimeric vaccinia virus
|
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
CA3116192C
(en)
|
2018-11-06 |
2025-09-23 |
Calidi Biotherapeutics (Nevada), Inc. |
IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
|
|
US11529402B2
(en)
|
2019-01-14 |
2022-12-20 |
Ignite Immunotherapy, Inc. |
Recombinant vaccinia virus and methods of use thereof
|
|
US11685904B2
(en)
|
2019-02-14 |
2023-06-27 |
Ignite Immunotherapy, Inc. |
Recombinant vaccinia virus and methods of use thereof
|
|
CA3155090A1
(en)
|
2019-09-20 |
2021-03-25 |
Transgene |
Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
|
|
BR112022011158A2
(pt)
|
2019-12-12 |
2022-08-30 |
Ignite Immunotherapy Inc |
Vírus vaccinia oncolítico variante e métodos de uso do mesmo
|
|
MX2022008547A
(es)
|
2020-01-09 |
2022-08-10 |
Pfizer |
Virus de vacuna recombinante.
|
|
MX2023000734A
(es)
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
CN112668865A
(zh)
|
2020-12-23 |
2021-04-16 |
贵阳市城市轨道交通集团有限公司 |
一种城市地铁风险动态分析方法
|